Tests lidocaine with usual pain care during sickle cell crisis
Tests whether lidocaine added to usual care lowers opioid use in sickle cell crisis.
Key facts
- Who runs it
- Centre Hospitalier Universitaire De Nantes
- Where
- Bordeaux, Les Abymes, Lille Cedex, Marseille, Nantes, ORLEANS, Paris Cedex 20, Poitiers, Rouen, Talence, Toulouse Cedex 9, and Tours, FranceSee the 12 sites
- Trial code
- Registry title
- Lidocaine for opioid sparing in vaso-occlusive crisis of Sickle Cell Disease
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 104 people, planned
- Started
- 3 Jul 2026
- Expected to end
- 3 Aug 2028
- Type of study
- Interventional
- Record updated
- 3 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with sickle cell disease who are in intensive care with a painful crisis or acute chest syndrome and have recently started morphine or oxycodone by injection or drip.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Sickle cell disease (SS, SC, Sβ0 or Sβ+ type). In intensive care mainly because of a vaso-occlusive crisis (acute pain) and/or acute chest syndrome (breathing signs with a new lung shadow on imaging).
- Earlier treatment
- Morphine or oxycodone given by injection or drip, started less than 72 hours before joining.
- Biomarker or test result
- Sickle cell genotype SS, SC, Sβ0 or Sβ+.
Main reasons for not taking part
- Pregnant or breastfeeding women
- On a breathing machine through a tube, or acute respiratory distress syndrome
- Epilepsy, or Glasgow coma scale below 13
- Heart rhythm or conduction problems, or heart failure
- Severe liver or kidney failure, or body weight under 40 kg (88 lb) or over 120 kg (265 lb)
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Age ≥18 years
- Known sickle cell disease with an SS, SC, Sβ0, or Sβ+ genotype
- Patient admitted to the intensive care unit for vaso-occlusive crisis and/or acute chest syndrome as the main reason for admission : Vaso-occlusive crisis defined by acute pain or tenderness, affecting at least one part of the body, including limbs, ribs, sternum, head (skull), spine, and/or pelvis, not attributable to other cause / Acute chest syndrome defined by the association of clinical respiratory sign(s): dyspnea and/or chest pain and/or auscultatory abnormality (crepitants and/or bronchial breathing) with a new pulmonary infiltrate on chest X-ray, thoracic CT-scan, or lung ultrasound
- Treatment with parenteral morphine or oxycodone started less than 72 hours prior to inclusion
- Patient or next of kin informed about the study and having consented to participation of the patient in the study. If patient is no competent and no next of kin can be contacted during screening for the study, trial inclusion will be completed as an emergency procedure by the intensive care unit physician, in compliance with French law
- French speaking
- Patient with health care insurance
Who cannot take part
- Prior inclusion in the study in the last 3 months
- Patient already enrolled in a clinical drug study
- Patients treated with anti-arhythmic drugs known to induce torsade de pointe
- Patients on chronic or occasional treatment with drugs that interact with the 3A cytochrome isoenzymes (CYP3A) and/or 1A2 cytochrome isoenzymes (CYP1A2)
- Chronic respiratory failure with long term non invasive ventilation (excluding Continuous Positive Air way pressure), or long term oxygen therapy at home
- Acute Respiratory Distress Syndrome according to The 2012 Berlin definition
- Acute or Chronic liver failure with MELD > 19
- Sickle cell disease acute complication other than vaso-occlusive crisis or acute chest syndrome as the main reason for admission : priapism, stroke, acute splenic sequestration, acute hepatic sequestration, bone marrow necrosis
- Known or assumed hypersensitivity to lidocaine hydrochloride, other local anaesthetics (e.g., bupivacaine or ropivacaine) or an excipient
- Known atrioventricular block, QT prolongation or other heart conduction disorder or heart failure
- Acute or Chronic kidney failure with clearance <30mL/min/m² according to CKD-EPI
- Pregnant women or nursing mothers; Women of child bearing potential will be tested for pregnancy before inclusion
- Patients with recurrent porphyria, porphyria in remission, or known asymptomatic carriage of gene mutations responsible for porphyria
- Patient under invasive mechanical ventilation
- Epileptic patients
- Altered consciousness with Glasgow coma scale <13
- Hypovolemic shock or shock of other cause at screening for inclusion
- Body weight <40kg and >120kg
- Patients under guardianship, curatorship or under legal protection
- Prisoners or subjects who are involuntarily incarcerated
- Patients wearing a lidocaine-medicated plaster at the time of screening for inclusion
Where in France
- Centre hospitalier Universitaire de BordeauxBordeaux, FranceTaking people
- Centre Hospitalier Universitaire De La GuadeloupeLes Abymes, FranceTaking people
- Centre Hospitalier Universitaire De LilleLille Cedex, FranceTaking people
- Hopital de la TimoneMarseille, FranceTaking people
- Centre Hospitalier Universitaire de NantesNantes, FranceTaking people
- Centre Hospitalier Universitaire d'OrléansORLEANS, FranceTaking people
- Hopital TenonParis Cedex 20, FranceTaking people
- Centre Hospitalier Universitaire de PoitiersPoitiers, FranceTaking people
- Centre Hospitalier Universitaire RouenRouen, FranceTaking people
- Centre Hospitalier Universitaire De BordeauxTalence, FranceTaking people
- IUCT-OncopoleToulouse Cedex 9, FranceTaking people
- Centre Hospitalier Régional Universitaire de ToursTours, FranceTaking people
About the trial
What the trial wants to find out
To determine whether adding lidocaine to standard of care in pain management during sever vaso-occlusive crisis has an effect on the cumulative opioid consumption expressed as morphine milligram equivalent (MME).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Lidocaine for opioid sparing in vaso-occlusive crisis of Sickle Cell Disease
- Plain-language title
- Tests lidocaine with usual pain care during sickle cell crisisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 3 September 2026